The Emergence of ICER in American Pharma
Joe Biden recently suggested that Medicare drug-price negotiations should follow the German model where negotiations between government and drugmakers are informed [...]
Michael L. Ryan of Bristol Myers Squibb Elected Board Chair of National Pharmaceutical Council
Today the National Pharmaceutical Council (NPC) announced that Michael L. Ryan, PharmD, Senior Vice President, Worldwide Value, Access, Pricing and [...]
Advanced Design Framework with Yannis Jemiai
The clinical trial design process has been irrevocably altered by cloud-based computing. Until recently, it would take a statistician a [...]
[Webinar] How Health Care Innovation Affects Life Expectancy and Patient Well-Being
The American Journal of Managed Care® recently hosted a webinar entitled "Bang for the Buck: How Health Care Innovation Affects [...]
ICER Releases Draft Evidence Report on Treatments for High Cholesterol
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report evaluating the comparative clinical effectiveness and [...]
[Podcast] How To Best Launch a Therapy For an Ultra-rare Disease?
In a special episode of Beyond the Molecule, Fishawack Health explores the rare disease space to reveal the perspectives of two [...]
How to Develop the Right Drugs and How to Pay for Them
Tune in to this health care podcast with drug affordability expert Dr. Bruce Rector as he discusses how to leverage [...]
COVID-19: Second Assessment Update
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
Huntsworth Acquires Nucleus Global
Huntsworth, an international healthcare and communications group, has announced an agreement to acquire Nucleus Global, one of the largest medical [...]
Value Assessment in the Context of COVID-19
Efforts to rapidly respond to the coronavirus pandemic have highlighted the need for credible, relevant, and timely information on the [...]
[Podcast] Is Fee-For-Service the Smoking Gun for U.S. Health Care Spending?
It is no secret that fee-for-service models incentivize physicians and health systems to perform more tasks than may be needed. [...]
What to know as ACA heads to the Supreme Court
On Tuesday, oral arguments began in the Supreme Court and the stakes could not be higher: the very fate of [...]
ICER Releases Statement on Racism in America
The Institute for Clinical and Economic Review (ICER) has pledged to do its part to combat institutionalized and systemic racism. [...]
Indication-Based Pricing Gaining Support in UK
A cross-sector expert panel to improve patient access to innovative cancer medicines in the UK recommended that drug prices should [...]
ICER Provides Second Update to Pricing Models for Remdesivir
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
[ICON White Paper] ICER’s Impact on Payer Decision-making
The Institute for Clinical and Economic Review (ICER) fills a gaping void for Health Technology Assessment in the United States. [...]
The Patient Not in the Room
Since 2009, the amount that workers pay for health insurance has increased 71% while wages have increased 26%--yet another demonstration [...]
A Third of States Weighing Moves to Spend Less on Drugs
As they grapple with the economic fallout of Covid-19, about 1/3rd of U.S. states are looking for different ways to [...]
Huge Disconnect Between Dollars Spent On U.S. Healthcare And Value Produced
The U.S. spends more on healthcare per capita than any other developed nation; more than $11,000 per person annually. However, [...]
Emergency Use Authorization for Pfizer’s Covid-19 Vaccine May do More Harm Than Good
Pfizer and BioNTech’s experimental Covid-19 vaccine candidate prevented more than 90% of infections in healthy volunteers. Based on these data, the companies [...]
Affordable Care Act Hinges Upon Today’s Supreme Court Arguments
Today the Supreme Court will hear oral arguments in California v. Texas. Nearly every corner of the healthcare industry, including [...]
Use of RWD and RWE to Support Drug Reimbursement Decision-Making in Asia
The REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group is drafting a new report entitled ‘Use [...]
Inovalon to Support National Vaccine Adherence Programs through its ONE® Platform
Today, leading provider of cloud-based platforms Inovalon (Nasdaq: INOV) announced the launch of the Inovalon ONE® Platform configuration supporting multiple national vaccine [...]
To Curb High Out-of-Pocket Costs, Drug Rebates Should Benefit Consumers
The Center for Medical Economics and Innovation at the Pacific Research Institute released a brief that concluded that one principal [...]
US Drug Pricing Reform Post-Election
COVID is going to take priority over drug pricing as a policy focus regardless of the outcome of the US [...]